Xingjuan Chao Sells 39,540 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,540 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $24.61, for a total transaction of $973,079.40. Following the transaction, the chief executive officer owned 767,191 shares in the company, valued at approximately $18,880,570.51. The trade was a 4.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Friday, August 21st, Xingjuan Chao sold 6,068 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $145,753.36.
• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total value of $714,870.00.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.15 during trading hours on Friday, reaching $24.72. The stock had a trading volume of 220,005 shares, compared to its average volume of 343,502. The company has a market cap of $948.70 million, a price-to-earnings ratio of -14.05 and a beta of 0.95. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $25.33. The business’s fifty day moving average is $20.57 and its two-hundred day moving average is $19.46. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, research analysts expect that CeriBell, Inc. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 28th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a report on Thursday. Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th. BTIG Research raised their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Finally, Canaccord Genuity Group boosted their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $24.40.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently bought and sold shares of CBLL. TimesSquare Capital Management LLC bought a new position in CeriBell in the 2nd quarter valued at $15,182,000. Royce & Associates LP acquired a new stake in CeriBell in the fourth quarter worth about $11,695,000. Bank of New York Mellon Corp acquired a new stake in shares of CeriBell during the 2nd quarter worth approximately $17,437,000. BlackRock Inc. bought a new stake in shares of CeriBell during the 2nd quarter valued at $37,657,000. Finally, Deutsche Bank AG acquired a new position in CeriBell in the second quarter valued at about $1,742,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.